Dulaglutide (Trulicity®)
⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy.
Dulaglutide is a recombinant GLP‑1R agonist fusion glycoprotein, produced in CHO cells. It is not a simple short synthetic peptide.
Basic Information
- CAS No.: 923950-08-7Therapeuti…
- Structure: Homodimer linked by disulfide bonds. Each monomer = modified GLP‑1 analog + peptide linker + modified human IgG4 Fc fragment
- Molecular Formula: \(\boldsymbol{C_{2646}H_{4044}N_{704}O_{836}S_{18}}\)National I…
- Molecular Weight: 62,561 Da (main glycosylated form)Therapeuti…
- Appearance: White to off-white lyophilized powder
- Solubility: Soluble in aqueous buffer
- Storage: Lyophilized powder at -20℃, protect from light and moisture; avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.
Development Background
Dulaglutide is developed by Eli Lilly, brand name Trulicity®, approved for clinical use for type 2 diabetes. It is a long-acting GLP‑1 fusion protein. Native GLP‑1 is rapidly degraded by DPP‑4 with half-life ~2 min. Dulaglutide uses amino acid mutation for DPP‑4 resistance and fuses GLP‑1 analog to IgG4-Fc domain. Larger molecular size reduces renal clearance, prolonging half-life to ~4.7 days, supporting once-weekly dosing. The IgG4-Fc is mutated to eliminate Fcγ receptor binding and minimize immunogenicity.PMC
Mechanism of Action (Research Findings)
- Activates GLP‑1 receptor (Class B GPCR), elevates intracellular cAMP.
- Glucose-dependent insulin secretion: Stimulates pancreatic β-cells to release insulin only under high glucose.
- Suppresses inappropriate glucagon secretion from α-cells, lowering hepatic glucose output.
- Delays gastric emptying, reduces postprandial blood glucose spikes.
- Reduces appetite via central GLP‑1 receptor activation in hypothalamus.
- Cardioprotective effects observed in T2DM models, lowering major adverse cardiovascular events.
- Resistant to DPP‑4 enzymatic degradation.
Research Areas
- GLP‑1 receptor pharmacology & GPCR signaling
- Type 2 diabetes glycemic control models
- Obesity, appetite regulation & energy metabolism
- Cardiovascular protection in diabetic animal models
- Pancreatic beta-cell survival and preservation
- Comparative pharmacokinetics of long-acting GLP‑1 fusion proteins








评价
目前还没有评价